PolyPid director reports stock option holdings
PolyPid Ltd. director Story Brooke reported an initial holding of stock options on Ordinary Shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PolyPid Ltd. director Story Brooke reported an initial holding of stock options on Ordinary Shares. The options cover 17,456 underlying Ordinary Shares at an exercise price of $4.01 per share and expire on February 4, 2036. According to the footnote, these options were granted on February 4, 2026 and vest on a quarterly basis beginning December 11, 2025, continuing through December 11, 2029.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock option (right to buy) | -- | -- | -- |
Footnotes (1)
- F1. The options were granted on February 4, 2026 and vest on a quarterly basis beginning December 11, 2025 until December 11, 2029.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position does Story Brooke report in PolyPid (PYPD)?
What are the key terms of Story Brooke’s PolyPid stock options?
Is Story Brooke’s ownership in PolyPid held directly or indirectly?
How long will Story Brooke’s PolyPid stock options remain exercisable?
AI-generated analysis. How Rhea-AI works. Not financial advice.